CARDLYTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.27 USD | -36.51% |
|
-33.64% | +0.65% |
| May. 09 | Craig-Hallum Adjusts Cardlytics Price Target to $12 From $18, Maintains Buy Rating | MT |
| May. 09 | Needham Adjusts Price Target on Cardlytics to $12 From $17, Keeps Buy Rating | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,616 | 3,921 | 2,199 | 191.7 | 361.5 | 703.3 | - |
| Enterprise Value (EV) 1 | 1,512 | 3,628 | 1,965 | 69.71 | 361.5 | 703.3 | 703.3 |
| P/E ratio | -87.3 x | -70 x | -16.6 x | -0.42 x | -2.5 x | -10.2 x | -13.5 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.68 x | 21 x | 8.23 x | 0.64 x | 1.17 x | 2.2 x | 1.91 x |
| EV / Revenue | 7.68 x | 21 x | 8.23 x | 0.64 x | 1.17 x | 2.2 x | 1.91 x |
| EV / EBITDA | 267 x | -504 x | -180 x | -4.24 x | 95.9 x | 37.2 x | 22.6 x |
| EV / FCF | 508 x | -301 x | -52.8 x | -3.48 x | - | 141 x | 113 x |
| FCF Yield | 0.2% | -0.33% | -1.89% | -28.7% | - | 0.71% | 0.88% |
| Price to Book | 11.6 x | 25.3 x | 3.21 x | 0.91 x | - | - | - |
| Nbr of stocks (in thousands) | 25,712 | 27,464 | 33,269 | 33,166 | 39,254 | 48,174 | - |
| Reference price 2 | 62.86 | 142.8 | 66.09 | 5.780 | 9.210 | 14.60 | 14.60 |
| Announcement Date | 3/3/20 | 3/1/21 | 3/1/22 | 3/1/23 | 3/14/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 210.4 | 186.9 | 267.1 | 298.5 | 309.2 | 320.2 | 368.9 |
| EBITDA 1 | 6.052 | -7.78 | -12.22 | -45.17 | 3.771 | 18.93 | 31.19 |
| EBIT 1 | -17.32 | -53.92 | -122.6 | -82.71 | -22.69 | -11 | 0.858 |
| Operating Margin | -8.23% | -28.85% | -45.9% | -27.71% | -7.34% | -3.44% | 0.23% |
| Earnings before Tax (EBT) | -17.14 | -55.42 | -136.4 | -466.7 | - | - | - |
| Net income 1 | -17.14 | -55.42 | -128.6 | -465.3 | -134.7 | -68.3 | -53 |
| Net margin | -8.15% | -29.65% | -48.13% | -155.85% | -43.56% | -21.33% | -14.37% |
| EPS 2 | -0.7200 | -2.040 | -3.990 | -13.92 | -3.690 | -1.430 | -1.080 |
| Free Cash Flow 1 | 3.18 | -13.01 | -41.63 | -55.08 | - | 4.986 | 6.206 |
| FCF margin | 1.51% | -6.96% | -15.59% | -18.45% | - | 1.56% | 1.68% |
| FCF Conversion (EBITDA) | 52.54% | - | - | - | - | 26.34% | 19.9% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 3/1/21 | 3/1/22 | 3/1/23 | 3/14/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 90.05 | 67.93 | 75.4 | 72.71 | 82.5 | 64.33 | 76.7 | 79 | 89.17 | 67.61 | 76.19 | 82.11 | 94.28 | 76.89 | 89.62 |
| EBITDA 1 | 2.559 | -10.54 | -15.78 | -12.71 | -6.139 | -6.091 | -4.073 | 3.946 | 9.989 | 0.226 | 1.773 | 6.871 | 11.07 | 0.024 | 4.383 |
| EBIT 1 | -16.41 | -20.41 | -26.14 | -23.18 | -12.99 | -12.67 | -11.27 | 11.52 | 3.294 | -6.024 | -5.718 | -0.599 | 3.405 | -7.373 | -3.209 |
| Operating Margin | -18.22% | -30.04% | -34.67% | -31.88% | -15.74% | -19.69% | -14.7% | 14.58% | 3.69% | -8.91% | -7.51% | -0.73% | 3.61% | -9.59% | -3.58% |
| Earnings before Tax (EBT) | -19.7 | 33.04 | -127.7 | 6.267 | -378.3 | 13.61 | - | - | - | - | - | - | - | - | - |
| Net income 1 | -11.84 | 33.04 | -126.3 | 6.267 | -378.3 | 13.61 | -23.51 | -23.97 | -100.8 | -24.28 | -17.6 | -15 | -11.4 | -19.83 | -15.25 |
| Net margin | -13.14% | 48.64% | -167.48% | 8.62% | -458.5% | 21.15% | -30.65% | -30.33% | -113.09% | -35.91% | -23.1% | -18.27% | -12.09% | -25.79% | -17.02% |
| EPS 2 | -0.3200 | 0.9100 | -3.750 | 0.1900 | -11.32 | 0.4000 | -0.6700 | -0.6300 | -2.740 | -0.5600 | -0.3600 | -0.3100 | -0.2300 | -0.4050 | -0.3100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/2/22 | 8/2/22 | 11/1/22 | 3/1/23 | 5/4/23 | 8/1/23 | 11/8/23 | 3/14/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | 104 | 293 | 233 | 122 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 3.18 | -13 | -41.6 | -55.1 | - | 4.99 | 6.21 |
| ROE (net income / shareholders' equity) | -17.6% | -15.5% | -30.3% | - | - | - | - |
| ROA (Net income/ Total Assets) | -1.01% | -7.19% | -4.59% | -8.58% | - | - | - |
| Assets 1 | 1,706 | 770.9 | 2,799 | 5,426 | - | - | - |
| Book Value Per Share | 5.400 | 5.640 | 20.60 | 6.330 | - | - | - |
| Cash Flow per Share | 0.4800 | - | -1.200 | -1.610 | - | - | - |
| Capex 1 | 8.28 | 5.41 | 3.11 | 1.17 | - | 1.6 | 1.6 |
| Capex / Sales | 3.93% | 2.89% | 1.16% | 0.39% | - | 0.5% | 0.43% |
| Announcement Date | 3/3/20 | 3/1/21 | 3/1/22 | 3/1/23 | 3/14/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
14.6
USD
Average target price
17.67
USD
Spread / Average Target
+21.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.65% | 703M | |
| +9.65% | 3,051B | |
| +6.79% | 83.97B | |
| +4.74% | 76.9B | |
| -13.91% | 54B | |
| +23.12% | 48.01B | |
| -24.39% | 46.47B | |
| +23.22% | 42.04B | |
| +62.94% | 38.34B | |
| -33.46% | 24.97B |
- Stock Market
- Equities
- CDLX Stock
- Financials Cardlytics, Inc.